Ellagic acid induces cell cycle arrest and apoptosis through TGF-β/Smad3 signaling pathway in human breast cancer MCF-7 cells

Chen,Hong-Sheng; Bai,Ming-Han; Zhang,Tao; Li,Guo-Dong; Liu,Ming

doi:10.3892/ijo.2015.2870

Ellagic acid induces cell cycle arrest and apoptosis through TGF-β/Smad3 signaling pathway in human breast cancer MCF-7 cells

Authors:
- Hong-Sheng Chen
- Ming-Han Bai
- Tao Zhang
- Guo-Dong Li
- Ming Liu
View Affiliations

Affiliations: Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Nangang, Harbin, Heilongjiang 150001, P.R. China
Published online on: February 3, 2015 https://doi.org/10.3892/ijo.2015.2870
Pages: 1730-1738

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer represents the second leading cause of cancer-related deaths among women worldwide and preventive therapy could reverse or delay the devastating impact of this disease. Ellagic acid (EA), a dietary flavonoid polyphenol which is present in abundance in pomegranate, muscadine grapes, walnuts and strawberries, has been shown to inhibit cancer cells proliferation and induce apoptosis. Here, we investigated the growth inhibitory effects of EA on MCF-7 breast cancer cells. In the present study, we first found that EA inhibits the proliferation of MCF-7 breast cancer cells mainly mediated by arresting cell cycle in the G0/G1 phase. Moreover, gene expression profiling of MCF-7 breast cancer cell line treated with EA for 6, 12 and 24 h was performed using cDNA microarray. A total of 4,738 genes were found with a >2.0-fold change after 24 h of EA treatment. Among these genes, 2,547 were downregulated and 2,191 were upregulated. Furthermore, the changes of 16 genes, which belong to TGF-β/Smads signaling pathway, were confirmed by real-time RT-PCR and/or western blot analysis. TGF-β/Smads signaling pathway was found as the potential molecular mechanism of EA to regulate breast cancer cell cycle arrest in vitro. Therefore, the regulation of TGF-β/Smads pathway in breast cancer cells could be a novel therapeutic approach for the treatment of patients with breast cancer. Further studies with in vitro models, as well as an analysis of additional human samples, are still needed to confirm the molecular mechanisms of EA in inhibition or prevention of breast cancer growth.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Dai Z, Nair V, Khan M and Ciolino HP: Pomegranate extract inhibits the proliferation and viability of MMTV-Wnt-1 mouse mammary cancer stem cells in vitro. Oncol Rep. 24:1087–1091. 2010.PubMed/NCBI
3	Larrosa M, Tomas-Barberan FA and Espin JC: The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem. 17:611–625. 2006. View Article : Google Scholar : PubMed/NCBI
4	Seeram NP, Adams LS, Henning SM, et al: In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 16:360–367. 2005. View Article : Google Scholar : PubMed/NCBI
5	Herrera MC and Luque de Castro MD: Ultrasound-assisted extraction for the analysis of phenolic compounds in strawberries. Anal Bioanal Chem. 379:1106–1112. 2004.PubMed/NCBI
6	Tsao DA, Chang HJ, Lin CY, et al: Gene expression profiles for predicting the efficacy of the anticancer drug 5-fluorouracil in breast cancer. DNA Cell Biol. 29:285–293. 2010. View Article : Google Scholar : PubMed/NCBI
7	Berger E, Rome S, Vega N, Ciancia C and Vidal H: Transcriptome profiling in response to adiponectin in human cancer-derived cells. Physiol Genomics. 42A:61–70. 2010. View Article : Google Scholar : PubMed/NCBI
8	Poulogiannis G, Luo F and Arends MJ: RAS signalling in the colorectum in health and disease. Cell Commun Adhes. 19:1–9. 2012. View Article : Google Scholar : PubMed/NCBI
9	Areshkov PO, Avdieiev SS, Balynska OV, Leroith D and Kavsan VM: Two closely related human members of chitinase-like family, CHI3L1 and CHI3L2, activate ERK1/2 in 293 and U373 cells but have the different influence on cell proliferation. Int J Biol Sci. 8:39–48. 2012. View Article : Google Scholar : PubMed/NCBI
10	Huang KF, Zhang GD, Huang YQ and Diao Y: Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway. Int Immunopharmacol. 12:334–341. 2012. View Article : Google Scholar
11	Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R and Royuela M: MAP kinases and prostate cancer. J Signal Transduct. 2012:1691702012. View Article : Google Scholar
12	Wang CY, Tsai AC, Peng CY, et al: Dehydrocostuslactone suppresses angiogenesis in vitro and in vivo through inhibition of Akt/GSK-3beta and mTOR signaling pathways. PLoS One. 7:e311952012. View Article : Google Scholar
13	Cirera-Salinas D, Pauta M, Allen RM, et al: Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle. 11:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
14	Dong Y, Ganther HE, Stewart C and Ip C: Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res. 62:708–714. 2002.PubMed/NCBI
15	Uhlmann F, Bouchoux C and Lopez-Aviles S: A quantitative model for cyclin-dependent kinase control of the cell cycle: revisited. Philos Trans R Soc Lond B Biol Sci. 366:3572–3583. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yu B, Lane ME and Wadler S: SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol. 64:1091–1100. 2002. View Article : Google Scholar : PubMed/NCBI
17	Maiti B, Li J, de Bruin A, et al: Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem. 280:18211–18220. 2005. View Article : Google Scholar : PubMed/NCBI
18	Cheng L, Rossi F, Fang W, Mori T and Cobrinik D: Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(−), p16^INK4A(+) tumor cells. J Biol Chem. 275:30317–30325. 2000. View Article : Google Scholar : PubMed/NCBI
19	Muller H, Moroni MC, Vigo E, Petersen BO, Bartek J and Helin K: Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. Mol Cell Biol. 17:5508–5520. 1997.PubMed/NCBI
20	Gui T, Sun Y, Shimokado A and Muragaki Y: The roles of mitogen-activated protein kinase pathways in TGF-beta-induced epithelial-mesenchymal transition. J Signal Transduct. 2012:2892432012. View Article : Google Scholar
21	Pardali E and Ten Dijke P: TGFbeta signaling and cardiovascular diseases. Int J Biol Sci. 8:195–213. 2012. View Article : Google Scholar
22	Attisano L and Wrana JL: Signal transduction by the TGF-beta superfamily. Science. 296:1646–1647. 2002. View Article : Google Scholar : PubMed/NCBI
23	Feng XH and Derynck R: Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 21:659–693. 2005. View Article : Google Scholar : PubMed/NCBI
24	Siegel PM and Massague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 3:807–821. 2003. View Article : Google Scholar : PubMed/NCBI
25	Moustakas A, Souchelnytskyi S and Heldin CH: Smad regulation in TGF-beta signal transduction. J Cell Sci. 114:4359–4369. 2001.
26	de Caestecker MP, Piek E and Roberts AB: Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst. 92:1388–1402. 2000. View Article : Google Scholar : PubMed/NCBI
27	Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
28	Levy L and Hill CS: Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17:41–58. 2006. View Article : Google Scholar
29	Chen CR, Kang Y, Siegel PM and Massague J: E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell. 110:19–32. 2002. View Article : Google Scholar : PubMed/NCBI
30	Coffey RJ Jr, Bascom CC, Sipes NJ, Graves-Deal R, Weissman BE and Moses HL: Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol Cell Biol. 8:3088–3093. 1988.PubMed/NCBI
31	Pietenpol JA, Holt JT, Stein RW and Moses HL: Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci USA. 87:3758–3762. 1990. View Article : Google Scholar : PubMed/NCBI
32	Hannon GJ and Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 371:257–261. 1994. View Article : Google Scholar : PubMed/NCBI
33	Warner BJ, Blain SW, Seoane J and Massague J: Myc downregulation by transforming growth factor beta required for activation of the p15^Ink4b G₁ arrest pathway. Mol Cell Biol. 19:5913–5922. 1999.PubMed/NCBI
34	Polyak K, Kato JY, Solomon MJ, et al: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8:9–22. 1994. View Article : Google Scholar : PubMed/NCBI
35	Laiho M, DeCaprio JA, Ludlow JW, Livingston DM and Massague J: Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell. 62:175–185. 1990. View Article : Google Scholar : PubMed/NCBI
36	Ramos C, Becerril C, Montano M, et al: FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 299:L222–L231. 2010. View Article : Google Scholar : PubMed/NCBI
37	Derynck R: TGF-beta-receptor-mediated signaling. Trends Biochem Sci. 19:548–553. 1994. View Article : Google Scholar : PubMed/NCBI
38	Claudio PP, Tonini T and Giordano A: The retinoblastoma family: twins or distant cousins? Genome Biol. 3:reviews3012. 2002. View Article : Google Scholar : PubMed/NCBI
39	Coqueret O: New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 13:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
40	Ko TC, Sheng HM, Reisman D, Thompson EA and Beauchamp RD: Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene. 10:177–184. 1995.PubMed/NCBI
41	Massague J and Polyak K: Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev. 5:91–96. 1995. View Article : Google Scholar : PubMed/NCBI
42	Robson CN, Gnanapragasam V, Byrne RL, Collins AT and Neal DE: Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol. 160:257–266. 1999. View Article : Google Scholar : PubMed/NCBI
43	Cam H and Dynlacht BD: Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell. 3:311–316. 2003. View Article : Google Scholar : PubMed/NCBI
44	Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ and Kouzarides T: Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 391:597–601. 1998. View Article : Google Scholar : PubMed/NCBI
45	Magnaghi-Jaulin L, Groisman R, Naguibneva I, et al: Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 391:601–605. 1998. View Article : Google Scholar : PubMed/NCBI